Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361342 | 0.86 | CTRC (0.33) | — | |
| SCHEMBL3477755 | 0.84 | EPHX2 (0.46) | ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL1098786 | 0.78 | TDP1 (0.39) | — | |
| SCHEMBL1515036 | 0.78 | CTRC (0.30) | — | |
| SCHEMBL6765107 | 0.77 | — | — | |
| SCHEMBL3370665 | 0.77 | — | — | |
| SCHEMBL2282763 | 0.75 | ALDH1A1 (0.46) | ALDH1A1NPSR1 | |
| SCHEMBL1097063 | 0.75 | — | — | |
| SCHEMBL11907411 | 0.75 | PTGS1 (0.48) | ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL1098333 | 0.74 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536509-B | Novel compounds as dual inhibitors of histone methyltransferase and DNA methyltransferase | 基础应用医学研究基金会 | 2020-06-09 | — | — | CN | disclosed |
| EP-3154957-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACION PARA LA INVESTIG MEDICA APLICADA (ES) | 2019-11-20 | — | — | EP | disclosed |
| US-9840500-B2 | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-12-12 | — | — | US | disclosed |
| US-20170121316-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-05-04 | — | — | US | disclosed |
| EP-3154957-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2017-04-19 | — | — | EP | disclosed |
| CN-106536509-A | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases | 基础应用医学研究基金会 | 2017-03-22 | — | — | CN | disclosed |
| WO-2015192981-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121316-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | DOT1L, DNMT3B, CARM1 | ALOX5 4562/4885PTGS1 3312/4885PTGS2 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.